Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at or call 800-767-3771 ext.  9339.

GW Pharmaceuticals (GWPH - Snapshot Report) recently submitted a marketing authorization application for Sativex in France as per the European Mutual Recognition Procedure (MRP). GW Pharma is looking to get Sativex approved for the treatment of spasticity due to multiple sclerosis (MS).

Earlier this month, Sativex was launched in Italy. In May 2013, GW Pharma received full marketing authorization for Sativex in Italy. GW Pharma also successfully reimbursed Sativex in Italy as a Class H (hospital dispensed) medicine. The price reimbursed in Italy is comparable to the price in Spain.

Following the launch, Sativex became the only drug in Italy containing cannabinoids, for the treatment of spasticity in MS.

Sativex is approved in 21 countries for the treatment of MS spasticity so far. The company is also seeking regulatory submission for the drug in other countries. GW Pharma is also looking to launch the drug in 8 European countries, and also in Australia and New Zealand.

We note that GW Pharma has a licencing agreement with Almirall S.A. for Sativex. As per the agreement, Almirall has the exclusive rights to market the drug in the European Union (excluding the UK), EU accession countries as well as Switzerland, Norway and Turkey. Almirall also has the rights to market the drug in Mexico. However, GW Pharma holds the rights to manufacture and supply Sativex to Almirall.

GW Pharma also has an agreement with Novartis (NVS - Snapshot Report) to commercialize Sativex in Australia, New Zealand, Asia (excluding Japan, China and Hong Kong), the Middle East (excluding Israel/Palestine) and Africa. As per the agreement, Novartis holds exclusive commercialization rights to Sativex and will also act as marketing authorization holder of the drug while GW Pharma will be responsible for the manufacture and supply of the drug.

GW Pharma is also conducting two phase III studies on the drug in the US for treating pain in cancer patients. The company expects top-line results from these studies by next year, after which it will file a New Drug Application (NDA) for the drug in the US.

GW Pharma presently carries a Zacks Rank #3 (Hold). However, other pharma stocks such as Jazz Pharmaceuticals (JAZZ - Analyst Report) and Sarepta Therapeutics, Inc. (SRPT - Snapshot Report) currently look better positioned with a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%